-200x200.jpg "Accu-Chek Active (50 Strips)")
Redia 50 mg tablet
Redia 50 mg tabletDescriptionVildagliptin, a member of the islet enhancer class, is a potent and selective dipeptidyl-peptidase-4 (DPP-4) inhibitor that improves glycaemic control: The administration of vildagliptin results in rapid and complete inhibition of DPP-4 activity. In patients with type 2 diabetes, administration of vildagliptin led to inhibition of DPP-4 enzyme activity for a 24-hour period. Vildagliptin inhibition of DPP-4 results in increased fasting and postprandial endogenous levels of the incretin hormones GLP-1 (glucagon-like peptide 1) and GIP (glucose-dependent insulinotropic polypeptide). By increasing the endogenous levels of these incretin hormones, vildagliptin enhances the sensitivity of beta cells to glucose resulting in improved glucose-dependent insulin secretion. Treatment with 50 to 100mg daily in patients with type 2 diabetes significantly improved markers of beta cell function. The degree of improvement in beta-cell function is dependent on the initial degree of impairment; in non-diabetic (normal glycaemic) individuals, vildagliptin does not stimulate insulin secretion or reduce glucose levels. By increasing endogenous GLP-1 levels, vildagliptin enhances the sensitivity of alpha cells to glucose, resulting in more glucose-appropriate glucagon secretion. The reduction in inappropriate glucagon during meals in turn attenuates insulin resistance. The enhanced increase in the insulin/glucagon ratio during hyperglycemia due to increased incretin hormone levels results in a decrease in fasting and postprandial hepatic glucose production, leading to reduced glycaemia.IndicationsRedia is indicated as an adjunct to diet and exercise to improve glycaemic control in patients with type 2 diabetes mellitus.As monotherapy,In dual combination with Metformin, a Sulphonylurea, a Thiazolidinedione, or Insulin when diet,exercise and a single antidiabetic agent do not result in adequate glycaemic control.SupplyRedia 50 mg Tablet: Each box contains 2x10 tablets in Alu-Alu blister pack...
Available for request
Viglita 50 mg tablet
Indication:ViglitaTM is indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus.Dosage & Administration:The recommended dose of ViglitaTM is 50 mg or 100 mg daily for monotherapy; 50 mg twice daily (morning and evening) when used in dual combination with Metformin or a Thiazolidinedione; 50 mg once daily in the morning when used in dual combination with a Sulphonylurea.Preparation:ViglitaTM 50 Tablet: Each box contains 20 tablets in blister pack...
Available for request
Vildapin 50 mg Tab
Vildapin 50 mg TabDescriptionVildagliptin is a potent and selective dipeptidyl peptidase-4 (DPP-4) inhibitor. It rapidly and completely inhibits DPP-4 activity and thus increases the levels of two incretin hormones GLP-1 (Glucagon-like peptide-1) and GIP (Glucose dependent insulinotropic polypeptide). Thus it enhances the sensitivity of beta cells to glucose, resulting in improved glucose-dependent insulin secretion. It also enhances the sensitivity of alpha cells to glucose by increasing endogenousGLP-1 levels, resulting in reduced glucagon secretion. The increase in the insulin/glucagon ratio during hyperglycemia due to increased incretin hormonelevels results in a decrease in fasting and postprandial hepatic glucose production leading to reduced glycemia.CompositionEach film-coated tablet contains Vildagliptin INN 50 mg.IndicationsVildapin is indicated for the treatment of type – 2 Diabetes mellitus.• As monotherapy• In dual combination with Metformin, a sulfonylurea, aThiazolidinedione or insulin when diet, exercise and a single antidiabetic agent do not result in adequate glycemic control.Dosage and AdministrationVildapin can be administered with or without food.As monotherapy and in dual combination with Metformin, aThiazolidinedione or insulin : 50 mg or 100 mg daily. The 50 mg dose should be administered once daily in the morning and the 100 mg dose should be administered as two divided doses of 50 mg in the morning and evening.In combination with a sulfonylurea : 50 mg once daily administered in the morning.Dosage in renal impairment : For mild renal impairment (Creatinine clearance≥ 50 ml/min) : No dose adjustment is required. For moderate to severe renal impairment : 50 mg once daily. For hemodialysis patients with end-stage liver disease should be used with caution.Dosage in hepatic impairment : Should not be used in patients with hepatic impairment.Or as directed by the physician.ContraindicationContraindicated in patients with known hypersensitivity to vildagliptin or any of the excipients.Side effectsThe most common side effects are nausea, peripheral edema, headache, tremor, asthenia and diziness.Precautions• Vildagliptin is not a substitute for insulin in insulin requiring patients• Should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis.• Liver function should be monitored before treatment and every 3 months for first year and periodically thereafter.• Should be used with caution in patients with heart failure.Use in Pregnancy and LactationPregnancy : Pregnancy Category B. There are no adequate and well- controlled studies in pregnant women. Vildagliptin should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.Lactation : It is not known whether Vildagliptin is excreted in human milk. It should not be exercised administered to a nursing mother.Pediatric UseSafety and effectiveness in children have not been established.Drug interactionVildagliptin has a low potential for drug interactions. Vildagliptin is not a cytochrome P450 enzyme substrate and it dose not inhibit or induce cytochromeP450 enzymes. So it is not likely to interact with co-medications that are substrates, inhibitors or inducers of these enzymes. No clinically relevant interactions with other oral anti diabetics (Glibenclamide, Pioglitazone,Metformin), Amlodipin, Digoxin, Ramipril, Simvastatin, Valsartan or warfarin were observed after co-administration with vildagliptin.SupplyEach box contains 2 x 10 tablets in alu-alu blister pack. ..
Available for request
